Live
- BJP releases ‘charge sheet’ against BJD govt
- District Nodal Officer Venkataramana announced the intermediate results
- She team that stopped child marriages
- Medical devices sector needs separate rules, says industry body AiMeD
- Andhra Paper declares lockout
- Opposition INDIA bloc working on 'one year, one PM' formula: PM Modi
- Delhi HC quashes FIR for outraging woman's modesty, orders man to assist Traffic Police for a month as settlement
- 'Apologise to families of farmers who committed suicide in Vidarbha', Amit Shah dares Sharad Pawar
- SC Collegium recommends appointment of a permanent judge in Chhattisgarh HC, extension of term of two judges
- U20 Men's football nationals: Telangana, Sikkim earn full points with easy win
FDA expands Merck drug's approval to treat lung cancer
Highlights
Federal health officials on Friday expanded approval of an innovative Merck drug to treat patients with an advanced form of the most common lung cancer. The Food and Drug Administration approved Keytruda for advanced non-small cell lung cancer patients who have seen their tumors spread after taking other therapies.
Federal health officials on Friday expanded approval of an innovative Merck drug to treat patients with an advanced form of the most common lung cancer. The Food and Drug Administration approved Keytruda for advanced non-small cell lung cancer patients who have seen their tumors spread after taking other therapies.
The disease accounts for roughly seven out of eight cases of lung cancer in the U.S. Regulators previously approved Keytruda in 2014 to treat melanoma, the deadliest form of skin cancer.
Keytruda is part of a promising new class of drugs called immunotherapy, which harness the body's immune system to help fight cancer. Merck's injectable biotech drug works by blocking a protein found in certain tumours called PD-1, which inhibits the body's natural response to cancer cells.
Next Story
ADVERTISEMENT
